These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29805707)

  • 1. Differential diagnostic roles of the serum CA19-9, total bilirubin (TBIL) and the ratio of CA19-9 to TBIL for benign and malignant.
    Liu W; Liu Q; Wang W; Wang P; Chen J; Hong T; Zhang N; Li B; Qu Q; He X
    J Cancer; 2018; 9(10):1804-1812. PubMed ID: 29805707
    [No Abstract]   [Full Text] [Related]  

  • 2. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
    La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
    World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
    J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diagnostic Value of the CA19-9 and Bilirubin Ratio in Patients with Pancreatic Cancer, Distal Bile Duct Cancer and Benign Periampullary Diseases, a Novel Approach.
    Boyd LNC; Ali M; Kam L; Puik JR; Rodrigues SMF; Zwart ES; Daams F; Zonderhuis BM; Meijer LL; Le Large TYS; Giovannetti E; van Laarhoven HWM; Kazemier G
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST and CA19-9/γ-GGT for jaundiced PDAC patients).
    Huang X; Lu Z; Zhang K; Wang G; Cai B; Wu P; Yin J; Miao Y; Jiang K
    Pancreatology; 2021 May; ():. PubMed ID: 34090807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
    Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
    Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.
    Sandanayake NS; Sinclair J; Andreola F; Chapman MH; Xue A; Webster GJ; Clarkson A; Gill A; Norton ID; Smith RC; Timms JF; Pereira SP
    Br J Cancer; 2011 Oct; 105(9):1370-8. PubMed ID: 21970875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of mass-forming autoimmune pancreatitis commonly misdiagnosed as a malignant tumor.
    Chen S; Zhang H; Fang F; Ye C; Zhang K
    Front Surg; 2023; 10():1017621. PubMed ID: 36761026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma.
    Qiu Y; He J; Chen X; Huang P; Hu K; Yan H
    Clin Chim Acta; 2018 May; 480():186-192. PubMed ID: 29438681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of serum IgG
    Tan L; Guan X; Zeng T; Wu S; Zheng W; Fu H; Long T; Wang Q; Meng Y; Tian Y; Yu J; Chen J; Li H; Cao L
    Scand J Gastroenterol; 2018 Feb; 53(2):206-211. PubMed ID: 29272982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.
    Lin MS; Huang JX; Yu H
    Int J Clin Exp Med; 2014; 7(3):744-50. PubMed ID: 24753772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R; Meyer-Wyss B; Herzog U; Tondelli P
    Schweiz Med Wochenschr; 1999 Jan; 129(3):77-9. PubMed ID: 10065510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review and Meta-analysis of Intraluminal Brachytherapy Versus Stent Alone in the Treatment of Malignant Obstructive Jaundice.
    Xu X; Li J; Wu J; Zhu R; Ji W
    Cardiovasc Intervent Radiol; 2018 Feb; 41(2):206-217. PubMed ID: 29075881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas.
    Zhao B; Cheng Q; Cao H; Zhou X; Li T; Dong L; Wang W
    BMC Cancer; 2021 May; 21(1):517. PubMed ID: 33962560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma.
    Leelawat K; Narong S; Wannaprasert J; Ratanashu-ek T
    World J Gastroenterol; 2010 Oct; 16(37):4697-703. PubMed ID: 20872971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.